Oncology News

ESMO oncology news ensures that you're always kept up to date with the latest developments that affect you and your daily practice. Make sure you check these pages frequently, or sign up to our newsletter.

Filter

Date Title Topic
24 Sep 2017 FDA Grants Accelerated Approval to Pembrolizumab for Advanced Gastric Cancer Gastrointestinal cancers - Cancer Immunology and Immunotherapy
24 Sep 2017 EMA Recommends Extensions of Therapeutic Indications for Nilotinib Haematologic malignancies - Cancer in Special Situations - Anticancer agents & Biologic therapy
21 Sep 2017 EMA Recommends Granting a Marketing Authorisation for Generic Imatinib Sarcomas - Haematologic malignancies - Anticancer agents & Biologic therapy
20 Sep 2017 Withdrawal of the Application for a Change to the Marketing Authorisation for Nivolumab in EU Cancer Immunology and Immunotherapy
19 Sep 2017 EMA Recommends Granting a Marketing Authorisation for Trastuzumab Biosimilar Breast cancer - Gastrointestinal cancers - Anticancer agents & Biologic therapy
18 Sep 2017 EMA Recommends Granting a Marketing Authorisation for Niraparib Gynaecologic malignancies - Anticancer agents & Biologic therapy
17 Sep 2017 FDA Approves a Biosimilar to Bevacizumab Anticancer agents & Biologic therapy
14 Sep 2017 Questionnaire Designed for Adolescent and Young Adults with Cancer Elicits Their Views on Treatment Cancer in Special Situations
13 Sep 2017 Reports on Care Quality for Adolescent and Young Adult Cancer Patients Are Lacking in the Literature Cancer in Special Situations
11 Sep 2017 ESMO 2017 Press Release: Best Poster at ESMO 2017 Shows Positive Trials Twice as Likely to be Reported in Lay Press
11 Sep 2017 ESMO 2017 Press Release: Best of ESMO 2017 Congress
10 Sep 2017 ESMO 2017: Adjuvant Dabrafenib Plus Trametinib Significantly Lowers Risk of Death in Stage III BRAF V600–Mutated Melanoma Melanoma and other skin tumours - Anticancer agents & Biologic therapy
10 Sep 2017 ESMO 2017: Nivolumab Bests Ipilimumab as Adjuvant Therapy in Resected Melanoma Melanoma and other skin tumours - Cancer Immunology and Immunotherapy
10 Sep 2017 ESMO 2017: BRIM8 Data Shows Benefit with Adjuvant Vemurafenib in Resected BRAFV600 Positive Melanoma Melanoma and other skin tumours - Anticancer agents & Biologic therapy
10 Sep 2017 ESMO 2017: Single Agent Atezolizumab in Head and Neck Cancer Head and neck cancers - Cancer Immunology and Immunotherapy